New financial models are changing how and where new drugs get developed. Promising molecules draw a dozen copycats right out the gate. The genuinely risky, boundary-pushing work often happens behind closed doors.

Endpoints editors sifted through the muddle to uncover eleven companies whose work clears the bar. These are the groups building the tools and making the scientific advances that help the industry take leaps forward.

Endpoints 11 is more than a list. It's a night where founders, investors and the editors who follow them come together in one room.

8 years of naming biotech's most promising startups